Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Executive Summary
Labeling for reduction of cardiovascular risk may help a bit with payers, but the "twin problem" of pricing and lack of patient adherence is likely to continue to present hurdles for reimbursement.
You may also be interested in...
Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year
Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.
Capricor’s Interim Data Could Offer Hope For Older DMD Patients
Although only interim data from six treated patients, Capricor’s Phase II DMD study shows improvements in upper limb performance, grip strength and respiration. Cardiac performance shows positive trend, but not yet statistical significance.
Can Sanofi Catch Up With Amgen Now That Praluent Has CV Risk-Reduction Claim?
ODYSSEY Outcomes data added to US label for Praluent; update includes claim for reduced cardiovascular incident risk and trial data indicating an all-cause mortality benefit.
Need a specific report? 1000+ reports available
Buy Reports